Enliven Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
ELVN$51.20-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · Additional Paid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance - January 1, 2024 | 41,292,027 | $41 | $400,172 | $141 | $(154,448) | $245,906 |
| Exercise of common stock options | 130,780 | — | 320 | — | — | 320 |
| Vesting of restricted stock units | 2,688 | — | — | — | — | — |
| Vesting of restricted stock awards and stock options | — | — | 73 | — | — | 73 |
| Issuance of common stock and pre-funded warrants in the Private Placement, net of issuance costs of $170 | 5,357,144 | 6 | 89,824 | — | — | 89,830 |
| Stock-based compensation | — | — | 4,515 | — | — | 4,515 |
| Net loss | — | — | — | — | (22,738) | (22,738) |
| Other comprehensive loss | — | — | — | (194) | — | (194) |
| Balance - March 31, 2024 | 46,782,639 | $47 | $494,904 | $(53) | $(177,186) | $317,712 |
| Exercise of common stock options | 357,277 | — | 1,859 | — | — | 1,859 |
| Vesting of restricted stock units | 1,749 | — | — | — | — | — |
| Vesting of restricted stock awards and stock options | — | — | 68 | — | — | 68 |
| Issuance of common stock under the ESPP | 31,801 | — | 320 | — | — | 320 |
| Issuance costs related to the Private Placement | — | — | (135) | — | — | (135) |
| Stock-based compensation | — | — | 5,144 | — | — | 5,144 |
| Net loss | — | — | — | — | (19,950) | (19,950) |
| Other comprehensive loss | — | — | — | (86) | — | (86) |
| Balance - June 30, 2024 | 47,173,466 | $47 | $502,160 | $(139) | $(197,136) | $304,932 |
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands, except share amounts)
| Common Stock · Additional Paid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance - January 1, 2025 | 48,936,459 | $49 | $553,213 | $55 | $(243,472) | $309,845 |
| Exercise of common stock options | 91,915 | — | 234 | — | — | 234 |
| Vesting of restricted stock units | 10,356 | — | — | — | — | — |
| Vesting of stock options | — | — | 33 | — | — | 33 |
| Stock-based compensation | — | — | 6,799 | — | — | 6,799 |
| Net loss | — | — | — | — | (28,544) | (28,544) |
| Other comprehensive loss | — | — | — | (71) | — | (71) |
| Balance - March 31, 2025 | 49,038,730 | $49 | $560,279 | $(16) | $(272,016) | $288,296 |
| Exercise of common stock options | 236,893 | — | 1,324 | — | — | 1,324 |
| Vesting of restricted stock units | 6,604 | — | — | — | — | — |
| Vesting of stock options | — | — | 28 | — | — | 28 |
| Issuance of common stock under the ESPP | 22,957 | — | 427 | — | — | 427 |
| Issuance of common stock and pre-funded warrants in the Public Offering, net of issuance costs of $13,875 | 9,920,987 | 10 | 216,159 | — | — | 216,169 |
| Stock-based compensation | — | — | 7,724 | — | — | 7,724 |
| Net loss | — | — | — | — | (25,335) | (25,335) |
| Other comprehensive loss | — | — | — | (161) | — | (161) |
| Balance - June 30, 2025 | 59,226,171 | $59 | $785,941 | $(177) | $(297,351) | $488,472 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.